A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Trial Profile

A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs Solriamfetol (Primary)
  • Indications Narcolepsy; Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TONES 3
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 10 May 2018 According to a Jazz Pharmaceuticals media release, data from this trial will be presented at the Annual Meeting of the Associated Professional Sleep Societies (SLEEP) (June 2018).
    • 02 Mar 2018 According to a Jazz Pharmaceuticals media release, the US FDA has accepted the New Drug Application (NDA) for solriamfetol (JZP-110) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is December 20, 2018.
    • 20 Dec 2017 According to a Jazz Pharmaceuticals media release, based on the results of this trial, comapny has submitted an New Drug Application (NDA) to the U.S. Food and Drug Administration, seeking for the marketing approval of solriamfetol (JZP-110) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top